Detalhe da pesquisa
1.
Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
JAMA Oncol
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662396
2.
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
Ther Adv Med Oncol
; 15: 17588359231200454, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789989
3.
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy.
Mol Oncol
; 17(6): 1060-1075, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37057719
4.
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
JAMA Surg
; 158(8): 807-815, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285140
5.
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.
NPJ Breast Cancer
; 8(1): 42, 2022 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35351903
6.
Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers.
Orphanet J Rare Dis
; 16(1): 363, 2021 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34399808
7.
Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
Cancers (Basel)
; 13(18)2021 Sep 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34572791